Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

New Triple-Action Drug Helps People With Diabetes Lose Up to 15% of Their Body Weight (opens in a new tab)

scitechdaily.com · 2026-10-19

Short answerEvidenceSource

Short answer

Mostly supported

Mostly supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 4 supported
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly supported

Every claim we could check holds up. Four of five claims match the study. This overall rating is based only on the claims we could check. One claim the study doesn't address.

  • 4 supported
  • 1 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredThe drug, called retatrutide, acts on three receptors involved in metabolism: GIP, GLP-1, and glucagon, unlike existing medications that activate one or two hormone receptors.View evidenceHide evidence

Why this verdict

The abstract profile supports that retatrutide is described as a triple hormone receptor agonist involving GIP, GLP-1, and glucagon. However, the comparative statement that existing medications activate only one or two receptors is not established in the supplied abstract-level profile, so that part is not verifiable at this depth.

1

Study evidence

At week 40, mean percent bodyweight change was −11.5% (SE 0.7) with retatrutide 4 mg, −13.9% (SE 0.8) with 9 mg, and −15.3% (SE 0.8) with 12 mg, versus −2.6% (SE 0.5) with placebo.Retatrutide 4 mg: −11.5% (SE 0.7); 9 mg: −13.9% (SE 0.8); 12 mg: −15.3% (SE 0.8); Placebo: −2.6% (SE 0.5)

“A key secondary endpoint was the percentage change in bodyweight from baseline to week 40.”
Claim 2 of 5SupportedAn experimental drug that targets three metabolic pathways has produced substantial improvements in blood sugar control and weight loss in people with type 2 diabetes.View evidenceHide evidence

As statedsubstantial improvements

Why this verdict

The abstract profile supports that once-weekly retatrutide, a triple hormone receptor agonist, produced clinically/statistically meaningful HbA1c reductions and substantial bodyweight loss in a phase 3 randomized placebo-controlled trial in adults with type 2 diabetes. The paper population is narrower than the claim’s broad wording: adults inadequately controlled with diet and exercise.

1

Study evidence

Retatrutide produced greater mean reductions in HbA1c from baseline to week 40 versus placebo.Mean change HbA1c: −1.69% (SE 0.11) 4 mg; −1.86% (0.10) 9 mg; −1.94% (0.08) 12 mg; placebo −0.81% (0.12). Estimated differences vs placebo: −0.88% (95% CI −1.18 to −0.59) 4 mg; −1.04% (−1.32 to −0.76) 9 mg; −1.12% (−1.39 to −0.85) 12 mg (all p<0.0001).

“In this 40-week, phase 3, randomised, double-blind, placebo-controlled trial at 48 sites in the USA, Mexico, and India”
2

Study evidence

At week 40, mean percent bodyweight change was −11.5% (SE 0.7) with retatrutide 4 mg, −13.9% (SE 0.8) with 9 mg, and −15.3% (SE 0.8) with 12 mg, versus −2.6% (SE 0.5) with placebo.Retatrutide 4 mg: −11.5% (SE 0.7); 9 mg: −13.9% (SE 0.8); 12 mg: −15.3% (SE 0.8); Placebo: −2.6% (SE 0.5)

“A key secondary endpoint was the percentage change in bodyweight from baseline to week 40.”
Claim 3 of 5SupportedIn a phase 3 clinical trial published in The Lancet, participants receiving the once-weekly injection lost an average of up to 15.3% of their body weight over 40 weeks, alongside significant reductions in long-term blood sugar levels.View evidenceHide evidence

As statedup to 15.3% of body weight over 40 weeks; HbA1c reduced by 1.69 to 1.94 percentage points

Why this verdict

The profile supports the trial design, once-weekly injection, 40-week timeframe, and the stated magnitudes: bodyweight change reached −15.3% in the 12 mg group, and HbA1c changes were −1.69% to −1.94% with statistically significant differences versus placebo. Because this was randomized and placebo-controlled, the causal framing for assigned treatment versus placebo is appropriate.

1

Study evidence

Retatrutide produced greater mean reductions in HbA1c from baseline to week 40 versus placebo.Mean change HbA1c: −1.69% (SE 0.11) 4 mg; −1.86% (0.10) 9 mg; −1.94% (0.08) 12 mg; placebo −0.81% (0.12). Estimated differences vs placebo: −0.88% (95% CI −1.18 to −0.59) 4 mg; −1.04% (−1.32 to −0.76) 9 mg; −1.12% (−1.39 to −0.85) 12 mg (all p<0.0001).

“In this 40-week, phase 3, randomised, double-blind, placebo-controlled trial at 48 sites in the USA, Mexico, and India”
2

Study evidence

At week 40, mean percent bodyweight change was −11.5% (SE 0.7) with retatrutide 4 mg, −13.9% (SE 0.8) with 9 mg, and −15.3% (SE 0.8) with 12 mg, versus −2.6% (SE 0.5) with placebo.Retatrutide 4 mg: −11.5% (SE 0.7); 9 mg: −13.9% (SE 0.8); 12 mg: −15.3% (SE 0.8); Placebo: −2.6% (SE 0.5)

“A key secondary endpoint was the percentage change in bodyweight from baseline to week 40.”
Claim 4 of 5SupportedThe trial did not directly establish how much each pathway contributed to the observed benefits, and longer-term safety remains under study.View evidenceHide evidence

Why this verdict

The trial profile describes a 40-week randomized comparison of retatrutide doses versus placebo, not an experiment separating the contributions of GIP, GLP-1, and glucagon receptor activity. The profile also lists the 40-week follow-up as a limitation and does not provide longer-term safety data, supporting the caveat that longer-term safety remains unresolved.

1

Study evidence

Retatrutide produced greater mean reductions in HbA1c from baseline to week 40 versus placebo.Mean change HbA1c: −1.69% (SE 0.11) 4 mg; −1.86% (0.10) 9 mg; −1.94% (0.08) 12 mg; placebo −0.81% (0.12). Estimated differences vs placebo: −0.88% (95% CI −1.18 to −0.59) 4 mg; −1.04% (−1.32 to −0.76) 9 mg; −1.12% (−1.39 to −0.85) 12 mg (all p<0.0001).

“In this 40-week, phase 3, randomised, double-blind, placebo-controlled trial at 48 sites in the USA, Mexico, and India”
2

Study evidence

Gastrointestinal adverse events were the most frequent events reported with retatrutide; they were generally mild to moderate and subsided over time.

“The most frequent adverse events with retatrutide were generally mild to moderate gastrointestinal events, which subsided over time.”
Claim 5 of 5SupportedThe study found gastrointestinal side effects were the most common adverse events, generally mild to moderate, and 2% to 5% of participants receiving retatrutide discontinued because of adverse events.View evidenceHide evidence

As stated2% to 5% discontinuation due to adverse events

Why this verdict

The safety profile directly reports that the most frequent adverse events with retatrutide were generally mild-to-moderate gastrointestinal events, that discontinuations due to adverse events were 2–5% with retatrutide versus 0% with placebo, and that these data came from the 40-week trial safety assessment.

1

Study evidence

Gastrointestinal adverse events were the most frequent events reported with retatrutide; they were generally mild to moderate and subsided over time.

“The most frequent adverse events with retatrutide were generally mild to moderate gastrointestinal events, which subsided over time.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Important population limitation: the trial evaluated retatrutide as monotherapy in adults with type 2 diabetes inadequately controlled with diet and exercise; patients already using glucose-lowering medications were not represented.

    The story says adults with type 2 diabetes and notes lack of direct comparison with current drugs, but it does not clearly convey that the enrolled population was limited to diet-and-exercise inadequate control and excluded people on glucose-lowering medications, which affects generalisability.

    From Phase 3 randomized, double-blind, placebo-controlled, multicentre, parallel-group trial

  • Funding source: the study was funded by Eli Lilly and Company.

    The paper profile lists industry funding as a limitation/potential competing-interest context, but the story caveats supplied do not mention it.

    From Phase 3 randomized, double-blind, placebo-controlled, multicentre, parallel-group trial; randomized, double-blind, place

5 things the story did carry across
  • Phase 3 randomized, double-blind, placebo-controlled trial of once-weekly subcutaneous retatrutide versus placebo over 40 weeks.
  • Primary glycaemic-control finding: retatrutide produced larger HbA1c reductions than placebo, with mean changes of −1.69% to −1.94% versus −0.81% for placebo.
  • Key secondary bodyweight finding: retatrutide produced dose-related mean bodyweight reductions up to −15.3% at week 40 versus −2.6% with placebo.
  • Safety and tolerability: gastrointestinal adverse events were most frequent and generally mild-to-moderate; discontinuations due to adverse events were 2–5%; no severe hypoglycaemia was reported; two deaths were judged unrelated to study drug.
  • Follow-up limitation: outcomes and safety in the supplied profile cover 40 weeks, so durability and longer-term safety beyond this period are not established.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoEvaluate the efficacy of once-weekly retatrutide monotherapy (4 mg, 9 mg, 12 mg) versus placebo on glycaemic control in adults with type 2 diabetes inadequately controlled with diet and exercise over 40 weeks (primary endpoint: change in HbA1c).Phase 3 randomized, double-blind, placebo-controlled, multicentre, parallel-group trialExpand

In plain English

Phase 3 randomized, double-blind, placebo-controlled trial (TRANSCEND-T2D-1) in adults with type 2 diabetes inadequately controlled with diet and exercise showed once-weekly retatrutide (4 mg, 9 mg, 12 mg) for 40 weeks produced larger mean reductions in HbA1c from baseline to week 40 versus placebo, together with substantial bodyweight loss; adverse events were mainly mild-to-moderate gastrointestinal events.

Key findings

  • Retatrutide produced greater mean reductions in HbA1c from baseline to week 40 versus placebo.Mean change HbA1c: −1.69% (SE 0.11) 4 mg; −1.86% (0.10) 9 mg; −1.94% (0.08) 12 mg; placebo −0.81% (0.12). Estimated differences vs placebo: −0.88% (95% CI −1.18 to −0.59) 4 mg; −1.04% (−1.32 to −0.76) 9 mg; −1.12% (−1.39 to −0.85) 12 mg (all p<0.0001).
  • Retatrutide produced substantial dose-dependent bodyweight reductions versus placebo at week 40.Mean percent change in bodyweight: −11.5% (SE 0.7) 4 mg; −13.9% (0.8) 9 mg; −15.3% (0.8) 12 mg; placebo −2.6% (0.5).
“In this 40-week, phase 3, randomised, double-blind, placebo-controlled trial at 48 sites in the USA, Mexico, and India”
What this piece can’t prove
  • Trial evaluated retatrutide as monotherapy in adults with type 2 diabetes inadequately controlled with diet and exercise (patients on glucose-lowering medications were not represented).
  • Follow-up duration in this report was 40 weeks.
  • Study was funded by Eli Lilly and Company (reported in abstract).

1 further detail could not be confirmed from the summary.

2human in vivoEvaluate the effect of retatrutide versus placebo on bodyweight (key secondary endpoint: percent change from baseline to week 40).Randomized, double-blind, placebo-controlled, parallel-group phase 3 trial (TRANSCEND-T2D-1)Expand

In plain English

In the 40-week, phase 3 randomized, double-blind, placebo-controlled TRANSCEND-T2D-1 trial, retatrutide (4 mg, 9 mg, 12 mg once weekly) produced larger mean percent reductions in bodyweight from baseline to week 40 than placebo in adults with type 2 diabetes inadequately controlled by diet and exercise.

Key findings

  • At week 40, mean percent bodyweight change was −11.5% (SE 0.7) with retatrutide 4 mg, −13.9% (SE 0.8) with 9 mg, and −15.3% (SE 0.8) with 12 mg, versus −2.6% (SE 0.5) with placebo.Retatrutide 4 mg: −11.5% (SE 0.7); 9 mg: −13.9% (SE 0.8); 12 mg: −15.3% (SE 0.8); Placebo: −2.6% (SE 0.5)
“A key secondary endpoint was the percentage change in bodyweight from baseline to week 40.”
What this piece can’t prove

2 further details could not be confirmed from the summary.

3human in vivoCharacterize the safety and tolerability of retatrutide versus placebo over 40 weeks (adverse events, discontinuations, severe hypoglycaemia, deaths).randomized, double-blind, placebo-controlled trialExpand

In plain English

In the 40-week randomized, double-blind, placebo-controlled TRANSCEND-T2D-1 trial, retatrutide-treated participants most frequently experienced mild-to-moderate gastrointestinal adverse events that tended to subside over time. Study-drug discontinuations due to adverse events occurred in 2–5% of retatrutide recipients versus 0% of placebo recipients. No severe hypoglycaemia events were reported. Two deaths occurred during the study, both in the retatrutide 4 mg group and reported as unrelated to the study drug.

Key findings

  • Gastrointestinal adverse events were the most frequent events reported with retatrutide; they were generally mild to moderate and subsided over time.
  • Study intervention discontinuations due to adverse events occurred in 2–5% of retatrutide-treated participants versus 0% of placebo-treated participants.2–5% (retatrutide) vs 0% (placebo)
“The most frequent adverse events with retatrutide were generally mild to moderate gastrointestinal events, which subsided over time.”
What this piece can’t prove
  • Study funded by Eli Lilly and Company (potential competing interest noted in abstract).

4 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial

Lancet (London, England) · 2026

Deep dive in Tessa (opens in a new tab)Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 36 candidate papers

Selected

Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial

Lancet (London, England) · 2026 · PubMed, Europe PMC, Crossref

Tessa (opens in a new tab)Source (opens in a new tab)
Candidate

Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.

The Lancet. Diabetes & Endocrinology · 2026 · PubMed, Crossref

Tessa (opens in a new tab)Source (opens in a new tab)
Candidate

Author response for "Insulin Efsitora Demonstrates Similar Efficacy and Safety Profiles to Insulin Icodec in Insulin-Experienced Individuals with Type 2 Diabetes Mellitus: A Matching-Adjusted Indirect Comparison"

2026 · Crossref

Source (opens in a new tab)

And 30 more candidates considered.